A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

Exclusion Criteria

• •Known hypersensitivity or idiosyncratic reaction to the API´s.
• •Clinical diagnosis of non-AGA forms of alopecia.
• •History of hair transplants.
• •Subject having dyed or bleached hair 12 months prior to study start.
• •Use of any topical product in the target region in the last 6 months.
• •A medical history of receiving chemotherapy/cytotoxic agents.
• •Uncontrolled hypertension.
• •Any dermatological disorders (eczema, psoriasis, sun damage, skin cancer).
• •Hormonal diseases such as thyroid disorders or diabetes.
• •Liver and kidney disease.
• •Smokers.
• •Drug or alcohol abuse within 12 months.
• •No written consent.
• •The receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the first dose of study drug.